|Description||The citrate salt form of Ixazomib which is a proteasome inhibitor. It is considered a rollover Phase II trial against multiple myeloma, amyloidosis and lymphoma in sorts of countries. IC50: 3.4 nM.|
|Related CAS||1201902-80-8; 1072833-77-2 (free base)|
|Appearance||White to off-white solid powder|
|Synonyms||4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid; MLN9708; MLN-9708; MLN 9708; ixazomib citrate MMLN-2238-prodrug Ixazomib-prodrug; Ninlaro|
|Solubility||DMSO 103 mg/mL; Water <1 mg/mL|
|Application||HDAC-IN-1, an analogue of MC 1568, is a Iia HDACs inhibitor that could probably influence myogenesis and adipogenesis.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Millennium Pharmaceuticals|
MG-132(S,R,S) is a reversible, cell permeable and selective tripeptide aldehyde proteasome inhibitor (IC50 = 0.22 μM), the most potent stereoisomer of MG-132. I...
AM 114 is an inhibitor of chymotrypsin-like activity of the 20S proteasome. In addition, AM-114 shows anticancer activity, It can inhibit cell growth in human c...
Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
Ixazomib is the biologically active form of MLN9708. Ixazomib exhibits an improved pharmacodynamic profile and antitumor activity compared with bortezomib in bo...
Carfilzomib is a tetrapeptide epoxyketone and an analog of epoxomicin, acting as a selective proteasome inhibitor, such as the chymotrypsin-like β5 subunit of t...
PI-1840 potently inhibits proteasomal CT-L activity with IC50 of 0.37 μM in intact human MDA-MB-468 cancer cells, and inhibits proliferation/survival of human M...
MG-101, also known as Calpain Inhibitor I and ALLN, is a calpain inhibitor (IC50 = 0.09 μM) that activates p53-dependent apoptosis in tumor cell lines. Activiti...
PMSF is an irreversible serine/cysteine protease inhibitor.